Johnson & Johnson’s $55 billion US commitment begins with Eastern NC plant groundbreaking
Executives mingled with North Carolina leaders in the city of Wilson to ceremonially break ground on Johnson & Johnson’s ...
J&J boosts US investments by 25% over 4 years amid looming tariff threats
Johnson & Johnson has laid out plans to raise U.S. investments by 25% to more than $55 billion over the next four years, as a ...
BioSpace3d
J&J Wins Crohn’s Expansion for Tremfya as Stelara Biosimilars Enter US Market
The label expansion could help J&J establish Tremfya as a successor to Stelara, which is now facing a growing biosimilar ...
Johnson & Johnson to Invest Over $55 Billion in U.S. in Next Four Years
Johnson & Johnson said it is increasing U.S investments to more than $55 billion over the next four years, boosting spending ...
Fierce Pharma3d
A closer look at pharma’s top patent losses in 2025
Johnson & Johnson’s Stelara, Regeneron’s Eylea and Amgen’s Prolia are just some of the drugs facing off against new ...
Fierce Pharma4d
J&J advances Stelara succession scheme with FDA nod for Tremfya in Crohn's disease
With another inflammatory bowel disease (IBD) approval in the bag for Tremfya, Johnson & Johnson continues to make good on ...
FDA approves Johnson & Johnson’s TREMFYA in Crohn’s disease
Johnson & Johnson announced that the FDA has approved TREMFYA, or guselkumab, the first and only IL-23 inhibitor ...
Esketamine Market Size, Growth Drivers And Global Forecast 2032 At A Thriving CAGR Of 7.90%
We use cookies and other tracking technologies to improve your browsing experience on our website, to show you personalized content and targeted ads, to analyze our website traffic, and to understand ...
Johnson & Johnson says FDA grants Fast Track designation to nipocalimab
Johnson & Johnson announced that the U.S. FDA has granted investigational nipocalimab Fast Track designation for the treatment of adult ...